Top menu

Pfizer’s buyback: Elixir for shareholders, jagged little pill for R&D

January 2, 2016 - Eric Reguly of the Globe and Mail, armed with theAIRnet’s research, charges that “North American-style capitalism obviously prefers buybacks” to innovation.

[Click HERE to access the paper via The Globe and Mail]

developed by bodhiWeb